6HLO image
Deposition Date 2018-09-11
Release Date 2019-01-16
Last Version Date 2024-01-24
Entry Detail
PDB ID:
6HLO
Title:
Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist Aprepitant
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.40 Å
R-Value Free:
0.22
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 21 21 21
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Substance-P receptor,GlgA glycogen synthase,Substance-P receptor
Gene (Uniprot):TACR1, PAB2292
Mutagens:L74A; V116I; A144L; M181K; A215L; W224R; K243A,L74A; V116I; A144L; M181K; A215L; W224R; K243A,L74A; V116I; A144L; M181K; A215L; W224R; K243A
Chain IDs:A
Chain Length:520
Number of Molecules:1
Biological Source:Homo sapiens, Pyrococcus abyssi GE5
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
YCM A CYS modified residue
Primary Citation
Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists.
Nat Commun 10 17 17 (2019)
PMID: 30604743 DOI: 10.1038/s41467-018-07939-8

Abstact

Neurokinins (or tachykinins) are peptides that modulate a wide variety of human physiology through the neurokinin G protein-coupled receptor family, implicated in a diverse array of pathological processes. Here we report high-resolution crystal structures of the human NK1 receptor (NK1R) bound to two small-molecule antagonist therapeutics - aprepitant and netupitant and the progenitor antagonist CP-99,994. The structures reveal the detailed interactions between clinically approved antagonists and NK1R, which induce a distinct receptor conformation resulting in an interhelical hydrogen-bond network that cross-links the extracellular ends of helices V and VI. Furthermore, the high-resolution details of NK1R bound to netupitant establish a structural rationale for the lack of basal activity in NK1R. Taken together, these co-structures provide a comprehensive structural basis of NK1R antagonism and will facilitate the design of new therapeutics targeting the neurokinin receptor family.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback